Literature DB >> 6853268

Lung damage in mice from cyclophosphamide and thoracic irradiation: the effect of timing.

C H Collis, G G Steel.   

Abstract

The development of lung damage in mice following thoracic irradiation is enhanced by cyclophosphamide (CY). CY was given at various times from 28 days before to 28 days after irradiation. Although increased damage was seen at all times, the extent showed marked variation according to the time interval. The most marked variations were seen when CY was given within 24 hours of irradiation; maximal enhancement was seen when CY was given before or with irradiation and minimal response when given 12 hrs before or 12 hrs after irradiation. It may therefore be prudent for the clinician to avoid such close time intervals between cytotoxic drugs and irradiation, unless a specific time-related therapeutic gain can be exploited.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853268     DOI: 10.1016/0360-3016(83)90235-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.

Authors:  Jennifer L Holter-Chakrabarty; Namali Pierson; Mei-Jie Zhang; Xiaochun Zhu; Görgün Akpek; Mahmoud D Aljurf; Andrew S Artz; Frédéric Baron; Christopher N Bredeson; Christopher C Dvorak; Robert B Epstein; Hillard M Lazarus; Richard F Olsson; George B Selby; Kirsten M Williams; Kenneth R Cooke; Marcelo C Pasquini; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

Review 2.  A survey of changing trends in modelling radiation lung injury in mice: bringing out the good, the bad, and the uncertain.

Authors:  Mohamad B Dabjan; Carolyn Ms Buck; Isabel L Jackson; Zeljko Vujaskovic; Brian Marples; Julian D Down
Journal:  Lab Invest       Date:  2016-08-01       Impact factor: 5.662

3.  The uptake of 3H-vincristine by a mouse carcinoma during a course of fractionated radiotherapy.

Authors:  G D Zanelli; L Rota; M Trovo; E Grigoletto; M Roncadin
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.